A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurrent/Metastatic Breast Cancer Previously Treated With Antibody-Drug Conjugates(MBC-EA-II-01)
NCT07520760 · RECRUITING · Phase 2
We track 5 ClinicalTrials.gov studies led by Sun Yat Sen University. The portfolio skews toward Phase 2 (3 trials).
5 clinical trials sponsored by Sun Yat Sen University.
| Phase | Trials | Distribution |
|---|---|---|
| Phase 2 | 3 | 60% |
| Phase 3 | 2 | 40% |
Sun Yat Sen University currently sponsors 5 clinical trials tracked on ReadTheTrial. These span Phase 2, Phase 3.
Sun Yat Sen University conducts research across multiple therapeutic areas. Browse the trial listings for details.
Yes, Sun Yat Sen University currently has 4 trials that are actively recruiting participants. Check individual trial pages for eligibility criteria and locations.